A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes
NCT ID: NCT00630851
Last Updated: 2015-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
249 participants
INTERVENTIONAL
2002-10-31
2004-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
NCT00711204
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
NCT00483028
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
NCT00096473
The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia
NCT00165815
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets
NCT01089582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Donepezil (Aricept)
Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
2
Placebo
Matching placebo tablets orally once daily for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Donepezil (Aricept)
Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
Placebo
Matching placebo tablets orally once daily for 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Living in skilled nursing home
Exclusion Criteria
* Musculoskeletal disease
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Fritsla, Sweden, Sweden
Pfizer Investigational Site
Alunda, , Sweden
Pfizer Investigational Site
Aneby, , Sweden
Pfizer Investigational Site
Avesta, , Sweden
Pfizer Investigational Site
Åkersberga, , Sweden
Pfizer Investigational Site
Årsta, , Sweden
Pfizer Investigational Site
Bengtsfors, , Sweden
Pfizer Investigational Site
Bergsjö, , Sweden
Pfizer Investigational Site
Boden, , Sweden
Pfizer Investigational Site
Borlänge, , Sweden
Pfizer Investigational Site
Degerfors, , Sweden
Pfizer Investigational Site
Eskilstuna, , Sweden
Pfizer Investigational Site
Eskilstuna, , Sweden
Pfizer Investigational Site
Gislaved, , Sweden
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Gullspång, , Sweden
Pfizer Investigational Site
Gustavsberg, , Sweden
Pfizer Investigational Site
Hedemora, , Sweden
Pfizer Investigational Site
Helsingborg, , Sweden
Pfizer Investigational Site
Ingelstad, , Sweden
Pfizer Investigational Site
Jönköping, , Sweden
Pfizer Investigational Site
Kalix, , Sweden
Pfizer Investigational Site
Karlstad, , Sweden
Pfizer Investigational Site
Katrineholm, , Sweden
Pfizer Investigational Site
Kristinehamn, , Sweden
Pfizer Investigational Site
Lidköping, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Munkfors, , Sweden
Pfizer Investigational Site
Nässjö, , Sweden
Pfizer Investigational Site
Oxie, , Sweden
Pfizer Investigational Site
Östersund, , Sweden
Pfizer Investigational Site
Partille, , Sweden
Pfizer Investigational Site
Rättvik, , Sweden
Pfizer Investigational Site
Sandviken, , Sweden
Pfizer Investigational Site
Särö, , Sweden
Pfizer Investigational Site
Sjuntorp, , Sweden
Pfizer Investigational Site
Sollebrunn, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Sunne, , Sweden
Pfizer Investigational Site
Trollhättan, , Sweden
Pfizer Investigational Site
Tullinge, , Sweden
Pfizer Investigational Site
Tyreso, , Sweden
Pfizer Investigational Site
Umeå, , Sweden
Pfizer Investigational Site
Upplands Vasby, , Sweden
Pfizer Investigational Site
Uppsala, , Sweden
Pfizer Investigational Site
Vaxjo, , Sweden
Pfizer Investigational Site
Vaxjo, , Sweden
Pfizer Investigational Site
Vännäs, , Sweden
Pfizer Investigational Site
Värnamo, , Sweden
Pfizer Investigational Site
Västerås, , Sweden
Pfizer Investigational Site
Visby, , Sweden
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2501017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.